Compare NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) (NWG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) vs Recursion Pharmaceuticals Inc — how do they compare? NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) trades at $17.13 (market cap $66.98B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) is far larger — about 31.3× Recursion Pharmaceuticals Inc's market cap, and NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) pays a 5.5% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) for 1 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| NWG | RXRX | |
|---|---|---|
Market Cap | $66.98B | $2.14B |
Volume | 5,259,060 | 30,789,535 |
Sector | Financials | Health |
52-Week High | $19.42 | $6.79 |
52-Week Low | $13.89 | $2.84 |
Typical Hold Time | 1 Days | 23 Days |
Enterprise Value | $140.55B | $1.66B |
Dividend Yield | 5.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares)
NatWest Group is a UK banking company serving personal, business, and institutional customers. Its services include deposits, lending, payments, and wealth management.
Read more on NWG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
